Literature DB >> 26129890

Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.

Ruta Petraitiene1, Vidmantas Petraitis2, John D Bacher3, Malcolm A Finkelman4, Thomas J Walsh5.   

Abstract

Galactomannan and (1→3)-β-D-glucan are useful biomarkers of invasive pulmonary aspergillosis (IPA). However, the effects of immunosuppression on levels of galactomannan or (1→3)-β-D-glucan in IPA are not well understood or quantified. We therefore studied the simultaneous levels of galactomannan and (1→3)-β-D-glucan in two rabbit models of experimental IPA: (1) AraC-induced neutropenia in untreated (UC-AraC) and liposomal amphotericin B-treated (LAMB-AraC) rabbits; and (2) nonneutropenic cyclosporine-methylprednisolone immunosuppression in untreated (UC-CsA+M) and LAMB-treated (LAMB-CsA+M) rabbits. Simultaneous levels of galactomannan and (1→3)-β-D-glucan were determined in bronchoalveolar lavage (BAL) fluid and serial serum specimens and correlated with pulmonary host response. Serum galactomannan index (GMI) and (1→3)-β-D-glucan concentration-time-curves were higher in UC-AraC vs. UC-CsA+M (Mann-Whitney U-test, P < .05). Serum galactomannan and (1→3)-β-D-glucan in treatment groups demonstrated therapeutic responses with similarly lower levels in comparison to UC (P < .01) in both models. Host differences did not affect BAL fluid GMI or (1→3)-β-D-glucan but did affect galactomannan and (1→3)-β-D-glucan levels in serum. The higher serum GMI and (1→3)-β-D-glucan concentration-time-curves in UC-AraC correlated with extensive pulmonary infiltration by angioinvasive hyphae and minimal inflammation, while the lower concentration-time-curves in UC-CsA+M were associated with shorter and fewer hyphae in lung tissue and an intensive neutrophil response to Aspergillus hyphae. Thus, serum levels of galactomannan and (1→3)-β-D-glucan in IPA depended upon immunosuppression, which also affected severity of infection and hyphal morphology, while BAL fluid galactomannan and (1→3)-β-D-glucan were sensitive biomarkers not affected by host response.
© The Author 2015. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  (1→3)-β-D-glucan; aspergillosis; galactomannan; immunosuppression; neutropenia

Mesh:

Substances:

Year:  2015        PMID: 26129890     DOI: 10.1093/mmy/myv034

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  11 in total

Review 1.  Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Authors:  Laura L Kovanda; Amit V Desai; William W Hope
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-08       Impact factor: 2.745

2.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children.

Authors:  Anna R Huppler; Brian T Fisher; Thomas Lehrnbecher; Thomas J Walsh; William J Steinbach
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

4.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 5.  Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses.

Authors:  Matthew W McCarthy; Ruta Petraitiene; Thomas J Walsh
Journal:  Int J Mol Sci       Date:  2017-05-24       Impact factor: 5.923

Review 6.  Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.

Authors:  Toine Mercier; Ellen Guldentops; Katrien Lagrou; Johan Maertens
Journal:  Front Microbiol       Date:  2018-04-04       Impact factor: 5.640

Review 7.  Treatment of Aspergillosis.

Authors:  Jeffrey D Jenks; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2018-08-19

Review 8.  Blood Aspergillus PCR: The Good, the Bad, and the Ugly.

Authors:  Matthias Egger; Jeffrey D Jenks; Martin Hoenigl; Juergen Prattes
Journal:  J Fungi (Basel)       Date:  2020-01-27

9.  Sputum signatures for invasive pulmonary aspergillosis in patients with underlying respiratory diseases (SPARED): study protocol for a prospective diagnostic trial.

Authors:  Wei Xiao; De-Ying Gong; Bing Mao; Xin-Miao Du; Lin-Li Cai; Min-Yu Wang; Juan-Juan Fu
Journal:  BMC Infect Dis       Date:  2018-06-11       Impact factor: 3.090

10.  [How I diagnose and treat invasive fungal diseases after hematopoietic stem cell transplantation].

Authors:  J Hu; L Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.